Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Department of Anesthesiology and Intensive Care Medicine, Karl Landsteiner Privatuniversität (KPU), Universitätsklinikum St. Pölten, St Pölten, Austria.
Diabetes Technol Ther. 2019 Oct;21(10):581-588. doi: 10.1089/dia.2019.0082.
This two-center pilot study combined for the first time an intra-arterial glucose sensor with a decision support system for insulin dosing (SGCplus system) in critically ill patients with hyperglycemia. Twenty-two patients who were equipped with an arterial line and required iv insulin therapy were managed by the SGCplus system during their medical treatment at the intensive care unit. Time to target was 111 ± 195 min (80-150 mg/dL) and 135 ± 267 min (100-160 mg/dL) in the lower and higher glucose target group. Mean blood glucose (BG) was 142 ± 32 mg/dL with seven BG values <70 mg/dL. Mean daily insulin dose was 62 ± 38 U and mean daily carbohydrate intake 148 ± 50 g/day (enteral nutrition) and 102 ± 58 g/day (parenteral nutrition). Acceptance of SGCplus suggestions was high (93%). The SGCplus system can be safely applied in critically ill patients with hyperglycemia and enables good glycemic control.
这项两中心的初步研究首次将动脉内葡萄糖传感器与胰岛素剂量决策支持系统（SGCplus 系统）结合用于合并高血糖的危重症患者。22 名患者在重症监护病房接受治疗时，配备动脉导管并需要静脉内胰岛素治疗，由 SGCplus 系统进行管理。目标时间为 111±195min（80-150mg/dL）和 135±267min（100-160mg/dL），在较低和较高血糖目标组中。平均血糖（BG）为 142±32mg/dL，有 7 个 BG 值<70mg/dL。平均每日胰岛素剂量为 62±38U，平均每日碳水化合物摄入量为 148±50g/天（肠内营养）和 102±58g/天（肠外营养）。对 SGCplus 建议的接受程度很高（93%）。SGCplus 系统可安全应用于合并高血糖的危重症患者，可实现良好的血糖控制。
